Elevated serum progastrin‐releasing peptide (31–98) in metastatic and androgen‐independent prostate cancer patients*

Yashi, Masahiro; Muraishi, Osamu; Kobayashi, Yutaka; Tokue, Akihiko; Nanjo, Hiroshi

doi:10.1002/pros.10063

Cited by 42 publications

(24 citation statements)

References 36 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levels of PSA are highly upregulated during prostate cancer progression (49). Pezzato et al report some new activities of PSA which include degradation of gelatin, degradation of type IV collagen in reconstituted basement membrane (Matrigel) and activation of progelatinase A (MMP-2), but not pro-MMP-9, in a cell-free system (50).…”

Section: Green Tea Polyphenols and Prostate Cancermentioning

confidence: 99%

Chemokines and B cells in renal inflammation and allograft rejection

Steinmetz¹

2009

Front Biosci

View full text Add to dashboard Cite

Green tea, the most popular beverage next to water, is a rich source of tea catechins and has potential to be developed as a chemopreventive agent for prostate cancer. For centuries it has been used in traditional medicine in Far-East countries. Male populations in these countries where large quantities of green tea are consumed on regular basis have the lowest incidence of prostate cancer. In this review, after a description of prostate cancer and several risk factors associated with the disease, we evaluated studies reported with green tea or its major constituent, (-)-epigallocatechin-3-gallate in inhibition of prostate cancer. This review provides an in-depth overview of various biochemical and signaling pathways affected by green tea in in vivo and in vitro models of prostate cancer. This is followed by a comprehensive discussion of the epidemiological studies and some ongoing clinical trials with green tea catechins. The review concludes with a brief discussion of the future direction and development of clinical trials employing green tea catechins which could be developed for prevention and/or intervention of prostate cancer.

show abstract

Section: Green Tea Polyphenols and Prostate Cancermentioning

confidence: 99%

Chemokines and B cells in renal inflammation and allograft rejection

Steinmetz¹

2009

Front Biosci

View full text Add to dashboard Cite

show abstract

“…Moreover, the serum CGRP levels of the hormone-resistant patients were significantly higher than those of the hormone-sensitive patients. Similar to other NE markers such as ProGRP, in stage D3 patients higher serum levels were observed than in stage D1 or D2 patients, and the measurement of the serum level is a potential parameter that affects androgen-independent progression [7,8] . Moreover, the serum CgA, NSE, and ProGRP reportedly have some significant prognostic information with or without measurement of PSA level [3][4][5]8] .…”

Section: Discussionmentioning

confidence: 71%

“…Prostate-specific antigen (PSA) is a very well-known tumor marker in the diagnosis of PCa [13] , and it reportedly correlates with the serum NE markers including CgA and ProGRP in the untreated PCa patients, but not in the PCa patients treated with HT [4,7] . Although we also analyzed the correlation between PSA and the serum CGRP level in the untreated PCa patients, no significant correlation was detected in our previous study [12] .…”

Section: Discussionmentioning

confidence: 99%

Significance of Serum Calcitonin Gene-Related Peptide Levels in Prostate Cancer Patients Receiving Hormonal Therapy

Suzuki¹,

Kobayashi²,

Morita³

2009

Urol Int

Self Cite

View full text Add to dashboard Cite

Background: Calcitonin gene-related peptide (CGRP) is one of the neuroendocrine markers. The serum CGRP levels in untreated prostate cancer (PCa) patients reportedly reflect the tumor volume and aggressiveness. However, the detailed evaluation of the serum CGRP levels in the PCa patients treated with hormonal therapy (HT) has never been reported. We measured the serum CGRP levels in PCa patients receiving HT to elucidate its clinical significance. Materials and Methods: We used serum samples from 129 PCa patients. Thirty-six patients had never received any treatment, and 93 had been treated with HT. The serum CGRP was measured by immunoradiometric assay, and we analyzed the correlation between the serum CGRP level and the clinicopathological factors. Results: The serum CGRP levels in the patients with higher clinical stages and histological grades were significantly higher than in those with lower stages and grades. Although in the patients treated with HT, the serum CGRP levels significantly correlated with clinical stage, these levels did not correlate with histological grade and the kind of HT. The highest serum CGRP level was observed in the stage D1 and stage D2 patients, not in the stage D3 patients treated with HT. Conclusion: The serum CGRP levels were significantly elevated in the PCa patients with high grade or high stage. However, in PCa patients receiving HT, various clinical factors influence the CGRP levels. Thus, evaluation of the levels should be careful.

show abstract

“…Several previous reports demonstrated that NE differentiation evaluated by CgA expression in the untreated prostate cancer specimens obtained by radical prostatectomy was not associated with the tumor stage and Gleason grade 1,3 . Among the circulating NE markers, CgA, NSE, and ProGRP were significantly associated with the clinical stage, but not with the histological grade probably due to the tumor volume dependency 7,8 , 10 . Although the number of patients entered in this study was small, the present study showed that the serum CGRP level was significantly associated with not only the tumor stage but also the histological grade, suggesting that CGRP may become potentially a new NE marker which reflects the tumor volume or aggressiveness.…”

Section: Discussionmentioning

confidence: 96%

Serum calcitonin gene‐related peptide levels in untreated prostate cancer patients

Suzuki¹,

Kobayashi²,

Morita³

2006

Int J of Urology

Self Cite

View full text Add to dashboard Cite

Background : The role of calcitonin gene-related peptide (CGRP) in prostate cancer has not been fully understood. Moreover, the serum CGRP level in prostate cancer patients has never been reported. We measured the serum CGRP levels in untreated prostate cancer patients to elucidate its clinical significance. Materials and methods : We used 36 serum samples from prostate cancer patients. All patients had never received any treatment. Serum CGRP was measured by immunoradiometric assay, and we analysed the association between serum CGRP level and clinicopathological factors. Results : Serum CGRP levels in the patients with higher clinical stages and histological grade were significantly higher than in those with lower stages and grade, respectively. But the levels did not correlate with the patient's age, liver or renal functions, serum prostate-specific antigen levels. Conclusion : Serum CGRP levels were significantly elevated in the patients with high grade or high stage untreated prostate cancer patients. Measurement of the serum CGRP may be a useful predictor of staging or grading of prostate cancer in the untreated prostate cancer patients.

show abstract

Elevated serum progastrin‐releasing peptide (31–98) in metastatic and androgen‐independent prostate cancer patients*

Cited by 42 publications

References 36 publications

Chemokines and B cells in renal inflammation and allograft rejection

Chemokines and B cells in renal inflammation and allograft rejection

Significance of Serum Calcitonin Gene-Related Peptide Levels in Prostate Cancer Patients Receiving Hormonal Therapy

Serum calcitonin gene‐related peptide levels in untreated prostate cancer patients

Contact Info

Product

Resources

About